Tofacent 10mg Tablet 10pcs

Uses of Tofacent 10mg Tablet

• Rheumatoid arthritis

How does Tofacent 10mg Tablet work?

Tofacitinib is a Janus kinase (JAK) inhibitor. By blocking JAKs, it prevents the phosphorylation and activation of STATs, key players in the inflammatory response, thereby reducing inflammation and joint damage.

Side Effects of Tofacent 10mg Tablet

Common adverse reactions (≥2% of patients):

• Upper respiratory tract infections
• Headache
• Diarrhea
• Nasopharyngitis

Quick Suggestions:

• Take Tofacent 10 at the same time each day.
• Regular blood tests are essential to monitor your health.
• Report any signs of infection immediately to your doctor.
• Do not receive live vaccines while on Tofacent 10.
• Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.
• Discuss any side effects, especially serious ones, with your doctor.

Indication of Tofacent 10mg Tablet

• Rheumatoid Arthritis: Tofacent is prescribed for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to or cannot tolerate methotrexate. It can be used alone or with methotrexate or other nonbiologic DMARDs.
• Psoriatic Arthritis: Tofacent is used for adults with active psoriatic arthritis who have had an inadequate response to or cannot tolerate methotrexate or other DMARDs.
• Ulcerative Colitis: Tofacent treats adults with moderately to severely active ulcerative colitis.

Pharmacology

Tofacitinib is a partial and reversible Janus kinase (JAK) inhibitor. It interferes with the body's response to cytokine signals by preventing the activation of the JAK-STAT pathway, thereby reducing inflammation and immune responses. This mechanism helps decrease tissue inflammation and joint damage in rheumatoid arthritis.

Dosage & Administration of Tofacent 10mg Tablet

• Rheumatoid Arthritis:
  • Standard: 5 mg twice daily or 11 mg once daily.
  • For patients with moderate/severe renal or moderate hepatic impairment: 5 mg once daily.
• Psoriatic Arthritis:
  • Standard: 5 mg twice daily or 11 mg once daily.
  • For patients with moderate/severe renal or moderate hepatic impairment: 5 mg once daily.
• Ulcerative Colitis:
  • Initial: 10 mg twice daily for at least 8 weeks.
  • Maintenance: 5 or 10 mg twice daily. Discontinue if no adequate therapeutic benefit is achieved after 16 weeks of 10 mg twice daily. Use the lowest effective dose to maintain response.
• Pediatric Use: Safety and effectiveness not established.
• Geriatric Use: Higher frequency of serious infections in patients 65 years and older. Use caution.
• Renal/Hepatic Impairment: Half the total daily dosage for patients with moderate/severe renal or moderate hepatic impairment.

Interaction

• Potent CYP3A4 Inhibitors (e.g., Ketoconazole): Dose adjustment to 5 mg once daily.
• Medications that moderately inhibit CYP3A4 and potently inhibit CYP2C19 (e.g., fluconazole): Dose adjustment to 5 mg once daily.
• Potent CYP Inducers (e.g., Rifampin): May reduce clinical response.

Do not initiate Tofacent if

• Absolute lymphocyte count <500 cells/mm³
• Absolute neutrophil count (ANC) <1000 cells/mm³
• Hemoglobin <9 gm/dL

Pregnancy & Lactation

• Pregnancy Category C: Use only if the potential benefit justifies the potential risk to the fetus.
• Lactation: Unknown if excreted in human milk. Weigh the potential for serious adverse reactions in nursing infants against the benefits of the drug for the mother.

Precautions & Warnings

• Serious Infections: Avoid use during active serious infections, including localized infections.
• Gastrointestinal Perforations: Use cautiously in at-risk patients.
• Laboratory Monitoring: Monitor lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids.
• Immunizations: Avoid live vaccines.

Storage Conditions:

• Store below 30°C.
• Protect from light and moisture.
• Keep out of reach of children.